Boston, MA, US & Lausanne, Switzerland, November 20, 2019: SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Milton Silva-Craig joined its Board of Directors, effective immediately. Mr. Silva-Craig brings over 25 years of experience holding executive positions in healthcare.

Silva-Craig is a successful leader who has demonstrated expertise in growing and scaling businesses in various fields of healthcare, including IT, medical imaging and quality data management. Since 2014, he has been the CEO of Q-Centrix, recently leading the company through an impressive sale from private equity firm Sterling Partners to TPG Growth, a leading global private investment firm. Prior to Q-Centrix, Milton served as president of TransUnion’s healthcare business unit developing and executing a strategic business plan focused on repositioning and growing the company in the healthcare marketplace resulting in an eightfold increase. He also served as the president and chief operating officer at Emageon Inc. accelerating revenues from less than a million to more than $100 million and eventually leading the company through a successful initial public offering on NASDAQ in 2005. Before that, Milton Silva-Craig held executive positions at General Electric Medical Systems.

“I am tremendously excited about joining SOPHiA GENETICS’ Board of Directors,” said Milton Silva-Craig. “I was impressed by the company’s vision and how quickly the team managed to make Data-Driven Medicine a reality, having already helped over 440,000 patients to date through more than 1,000 hospitals. As part of my personal and professional commitment to improving healthcare, it is a unique opportunity to be part of the SOPHiA journey and helping the company reach its future goals.”

“We are thrilled to have Milton join SOPHiA’s journey in such an exciting stage in the company’s evolution,” added Jurgi Camblong, CEO and co-founder of SOPHiA GENETICS. “Given his success in growing and scaling health companies rapidly and his experience in data-driven systems, Milton’s guidance will be essential in capturing and leveraging multi-modality new-generation data and improving health outcomes and economics worldwide.”

With the addition of Troy Cox, former CEO of Foundation Medicine, Milton Silva-Craig is the second US-based executive to join the board of SOPHiA GENETICS this year, confirming the rapid market penetration of the company in the US, and its commitment to meet the growing demand across the country.

SOPHiA Whole Exome Solution (WES) now includes accurate CNV detection, making it a powerful application for healthcare professionals in their fight against rare diseases.

Houston, Texas, USA – 18th October 2019: SOPHiA GENETICS, leader in Data-Driven Medicine, announced today at the American Society of Human Genetics Annual Meeting (ASHG) the release of the new version of SOPHiA Whole Exome Solution. This advanced genomic application is reducing the overall turnaround time, thus accelerating rare disease characterization.

Rare diseases affect roughly 400 million people globally¹ . Their cause is genomic in approximately 80%² of cases. Whole exome analysis has become key as it is extremely powerful in helping experts detect rare diseases, but it remains very challenging. A large amount of information is gathered, making it difficult to properly detect important DNA variations such as CNVs. However, an accurate identification of CNVs is crucial: on average, CNVs are present in almost 10% of affected patients and can account for up to 35% of pathogenic variants³.

Leveraging the analytical power of SOPHiA to further support researchers, the newly released WES application offers healthcare institutions a standardized genomic solution with exceptional analytical performance. It includes high resolution (2-5 exons) CNV detection in a single workflow without the need for any reference sample.

In addition to existing interpretation functionalities such as the ACMG automated variant classification guidelines, virtual gene panels, and the variant filter builder, SOPHiA WES now includes Familial Variant Analysis (trio analysis) to automatically filter variants based on different inheritance modes.

“We use constant feedback we receive from genomic experts worldwide to match the needs and means of clinical researchers for their genomic investigations,” says Gioia Althoff, Vice President Genomics Business Area at SOPHiA GENETICS." SOPHiA WES now integrates CNV calling with unparalleled resolution at the exonic level, offering accurate detection of multiple types of variants in a single workflow.”

The updated SOPHiA Whole Exome Solution helps professionals globally manage the daunting amount of detected variants and focus solely on the most relevant ones. With this release, SOPHiA confirms its commitment to overcome barriers in adopting complex genomic applications worldwide by offering robust and standardized solutions.

---

^[1]https://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf?ua=

^[2] https://www.eurordis.org/about-rare-diseases

[3]Truty et al 2018, Genetics in Medicine volume 21, pages 114–123 (Nature 2019)

Lausanne, Switzerland, and Boston, United States, September 19, 2019: SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Gaëtan Fraikin and Sergei Yakneen have joined its executive team as Chief Marketing Officer and Chief Information Officer, respectively. Mr. Fraikin and Mr. Yakneen bring decades of highly specialized experience from key players in the health tech industry.

“Gaëtan and Sergei’s arrivals show our continued efforts to democratize Data-Driven Medicine worldwide. They both share our vision and perfectly understand the next opportunities they will help achieve,” affirmed Jurgi Camblong, CEO and co-founder of SOPHiA GENETICS.

Gaëtan Fraikin brings unmatched experience building and launching diagnostic and medical device brands. He has worked with hundreds of clients including Illumina, 23andMe, Grail, Genentech, Merck, Amgen, Invitae, Quest Diagnostics and LabCorp while driving his own branding and advertising agency Audacity. More recently, he led global marketing and branding at Illumina and Roche Sequencing, where he successfully helped launch flagship products NovaSeq and Harmony NIPT.

“SOPHiA is building the future of diagnostics and healthcare in cancer and rare diseases. Their unique approach relies on pulling from multiple sources of data, starting with genomics, adding radiomics and others in the future, to build multi-dimensional models of disease,” said Fraikin. “SOPHiA also leverages the power of global collaboration through its fast-growing network of 1,000+ partners. I am thrilled to be joining this journey and to help accelerate the realization of this vision and impact the lives of millions worldwide.”

Dr. Sergei Yakneen has proven himself as an accomplished scientific researcher, technologist and leader. He led the technical working group of the world’s largest international cancer genome analysis project, the Pan Cancer Analysis of Whole Genomes, and devised new distributed computing methods for analysis of genomic data at scale. He has managed technology teams of various sizes, from small startups to global tech giants. He launched Amazon.com’s first software engineering organization in the Toronto area.

“I am extremely excited to be joining the SOPHiA GENETICS team as CIO and to take an already excellent product to the next level. We will continue to build upon the great work that’s been produced over the years, and further deliver the positive impact of our global approach throughout the community!" said Yakneen.

Sergei is taking over the role of CIO previously held by Adam Molyneaux who had a dual role of CIO and Chief Architect. Going forward, Adam will fully dedicate his expertise to continue grow and scale the SOPHiA Platform, as Chief Architect.

Study to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) inrelapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Lausanne, Switzerland, August 6, 2019– ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and SOPHiA GENETICS, a leader in Data-Driven Medicine, today announced they have entered into a collaboration to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine). ADC Therapeutics is currently evaluating ADCT-402 in a pivotal Phase II clinical trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

SOPHiA GENETICS will conduct somatic mutation analysis of more than 4,000 genes in cell-free DNA (cfDNA) samples extracted from blood of DLBCL patients participating in ADC Therapeutics’ Phase II trial. SOPHiA technology will match detected genomic markers with clinical response to ADCT-402. The analytical power of SOPHiA for the detection of cancer mutations is key for this new development phase and illustrates the benefits of adopting Data-Driven Medicine applications for clinical trials.

“Our collaboration with SOPHiA GENETICS has the potential to uncover genomic mutations that correlate with clinical response to ADCT-402,” stated Patrick van Berkel, Senior Vice President of Research and Development at ADC Therapeutics. “We have observed significant single-agent clinical activity in our pivotal Phase II trial of ADCT-402 in a broad population of patients with relapsed or refractory diffuse large B-cell lymphoma. The insights from this collaboration will allow us to better identify and understand the characteristics of patients who respond best to treatment. We look forward to the results of this research enabled by SOPHiA’s unique platform.”

“We are pleased to partner with ADC Therapeutics, a leader in antibody drug conjugate development, to provide advanced biomarker analysis and turn the results into actionable insights that can improve clinical outcomes for patients and pave the way towards a new era in drug development,” said Esteban Czwan, Senior Vice President BioPharma at SOPHiA GENETICS. 

roy Cox joins SOPHiA GENETICS as the company expands its decentralized approach to Data-Driven Medicine to foster a sustainable and inclusive healthcare system.

Lausanne, SWITZERLAND, July 2, 2019: SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Troy Cox joined its Board of Directors, effective immediately. Mr. Cox, who previously held the position of Chief Executive Officer of Foundation Medicine, brings extensive knowledge of the biopharmaceutical industry to SOPHiA GENETICS.

A precision medicine pioneer, Troy Cox’s commitment to improve the lives of patients at Foundation Medicine (FMI) was recognized by the acquisition of the company by Roche in 2018. Prior to FMI, he served as Senior Vice President and Officer at Genentech, where he led US BioOncology for a period of unprecedented growth, participating in the launch of nearly half of the products from the world’s oncology leader. Earlier on, Mr. Cox held executive and senior positions with broad accountabilities and achievements for numerous companies in healthcare, including UCB BioPharmaceuticals, Sanofi-Aventis, and Schering-Plough.

“We warmly welcome Troy Cox to the SOPHiA GENETICS team,” said Jurgi Camblong, CEO and co-founder of SOPHiA GENETICS. “His extensive experience and past achievements bring significant added expertise to our Board. Troy shares the vision of SOPHiA of a decentralized approach to Data-Driven Medicine, fostering a sustainable and inclusive healthcare system where patients can be diagnosed and treated with the highest quality of care wherever they live.”

“I am proud to serve on the Board of such an innovative company, uniquely positioned to leverage the benefits of Data-Driven Medicine to make a difference in patients’ lives worldwide. This spirit drove me my entire career, and I’m happy to be able to pursue this mission in a truly inclusive and sustainable manner with SOPHiA GENETICS”, said Troy Cox. 

Lausanne, SWITZERLAND – 11 April 2019: SOPHiA GENETICS, global leader in Data-Driven Medicine, announced today the CE-IVD marking of its Solid Tumor Solution (STS), a new step in the fight against cancer. This standardized molecular diagnostic application precisely detects and characterizes all types of genomic alterations in 42 clinically relevant genes associated with a range of solid tumors such as lung, colorectal, skin and brain cancers.

Cancer is responsible for an estimated 9.6 million deaths in 2018, making it the second leading cause of death globally[1].“As about 1 in 6 deaths is due to cancer nowadays, it is essential to give patients an early and precise diagnosis. The newly approved CE-IVD Solid Tumor Solution represents a major advancement in the personalization of cancer care. It is designed to maximize diagnostic yield and guide treatment and management decisions,”says Gioia Althoff, Senior Vice President Genomics at SOPHiA GENETICS.

The STS leverages the full power of SOPHiA, the leading technology of choice for streamlined Data-Driven Medicine applications. In oncology, SOPHiA helps clinicians with decision support functionalities based on precision medicine intelligence. It enables simple, central access to relevant therapeutic, prognostic and diagnostic databases to determine the actionability and clinical significance of genomic alterations associated with the cancer type.

The solution has been highly optimized to deliver exceptional accuracy and precision. It can detect single nucleotide variants (SNVs), insertions, deletions (Indels) and gene amplification events. It also identifies microsatellite instability (MSI) status in 6 unique loci associated with colorectal cancer, which is currently recommended for all patients with this disease.

The CE-IVD marking for STS demonstrates the commitment of SOPHiA GENETICS in maintaining a firm focus on delivering robust, dependable and accessible solutions to hospitals all over the world, including some 920 hospitals to date. With the help of SOPHiA’s collective expertise and global network, healthcare professionals can confidently adopt standardized Data-Driven Medicine applications as a part of their routine workflow.

“Personalizing cancer care requires precision in the analysis, clinical interpretation and reporting. The Solid Tumor Solution by SOPHiA GENETICSis a quality-approved solution that helped us streamline the genomic testing workflow and get clinical-grade performance.With the STS, our lab has access to a comprehensive solution that accurately detects clinically relevant genomic alterations associated with solid tumors, accelerating the clinicians’ ability to diagnose patients and deliver the best treatment options,” comments Dr. José Antonio López-Guerrero, Head of Molecular Biology Laboratory at the Instituto Valenciano de Oncología (IVO) – Valencia, Spain.

---

[1]Reference: www.who.int/news-room/fact-sheets/detail/cancer

San Francisco, Jan. 4, 2019: SOPHiA GENETICS, a leading health tech company, announced today the closing of a $77 million investment round to accelerate the democratization of Data- Driven Medicine. The round was led by Generation Investment Management, a pioneer of sustainable investing, with offices in London and San Francisco. Generation were joined by Idinvest Partners, a European leader in private equity, alongside existing investors including Balderton Capital and Alychlo.

SOPHiA GENETICS was founded in Switzerland and is now co-based in Lausanne and Boston. The company combines deep expertise in life sciences and medical disciplines with mathematical capabilities in data computing. Today, its universal platform, SOPHiA AI, is utilized by more than 850 hospitals across 77 countries and has already supported the diagnosis of over 300,000 patients. The platform enables healthcare professionals to make sense of complex genomic and radiomic data through advanced analysis in order to better diagnose and treat patients, both for oncology and hereditary disorders.

With the new funding round, SOPHiA GENETICS has now raised a total of $140 million. This latest investment will allow the company to further grow the global community of hospitals using its technology. In particular, SOPHiA GENETICS will continue adding talent to reinforce its rapidly expanding presence in the US.

“Generation are delighted to partner with SOPHiA GENETICS. We believe that leveraging genetic sequencing and advanced digital analysis will enable a more sustainable healthcare system. SOPHiA GENETICS is a leader in the preventive and personalized medicine revolution, enabling the development of targeted therapeutics, thereby vastly improving health outcomes” said Lilly Wollman, co-head of Generation’s Growth Equity team. “We admire SOPHiA GENETICS not just for its differentiated analytics capability across genomic and radiomic data, but also for its exceptional team and culture”.

“Since we founded the company, our goal has been to help make the global healthcare system more sustainable. By helping clinical researchers leverage their expertise and work together as a community, patients all over the world can receive equal access to better care. Generation Investment Management and SOPHiA GENETICS are guided by the same belief. With Generation’s support, we will enable the more rapid adoption of Data-Driven Medicine technology in healthcare for the benefit of patients worldwide,” commented Dr. Jurgi Camblong, CEO and Founder of SOPHiA GENETICS.